Categories Earnings Call Transcripts, Health Care

Cronos Group Inc. (CRON) Q4 2021 Earnings Call Transcript

CRON Earnings Call - Final Transcript

Cronos Group Inc.  (NASDAQ: CRON) Q4 2021 earnings call dated Mar. 01, 2022

Corporate Participants:

Shayne Laidlaw — Investor Relations

Kurt T. Schmidt — President, Chief Executive Officer

Robert L. Madore — Chief Financial Officer

Michael Ryan Gorenstein — Executive Chairman

Analysts:

Andrew Carter — Stifel — Analyst

Michael Freedman — Raymond James — Analyst

John Zamparo — CIBC Capital Markets — Analyst

Gaurav Jain — Barclays — Analyst

Andrew — Jefferies — Analyst

Michael Lavery — Piper Sandler — Analyst

Presentation:

Operator

Good morning, my name is Myra and I’ll be your conference operator today. I would like to welcome everyone to Cronos Group’s 2021, Fourth Quarter and Full Year Earnings Conference Call. Today’s call is being recorded. At this time, I would like to turn the call over to Shayne Laidlaw, Investor Relations. Sir, please go ahead.

Shayne Laidlaw — Investor Relations

Thank you, Myra and thank you for joining us today to review Cronos Group’s 2021 fourth quarter and full-year financial and business performance. Today, I am joined by our President and CEO, Kurt Schmidt; our CFO, Bob Madore and our Executive Chairman Mike Gorenstein. Cronos Group issued a news release announcing these financial results this morning which are filed on our EDGAR and SEDAR profiles. This information as well as the prepared remarks will also be posted on our website under Investor Relations.

Before I turn the call over to Kurt, I would like to remind you that our discussion during this conference call will include forward-looking statements that are based on assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements, including as a result of the factors described in the cautionary statements and risk factors included in the company’s earnings release and regulatory filings, including the company’s most recent annual report and Form 10-K.

By which any forward-looking statements made during this call are qualified in their entirety. In addition, during this call, certain financial measures may be discussed that are not recognized under the U.S. Generally Accepted Accounting Principles referred to by the Securities and Exchange Commission as non-GAAP measures we believe these non-GAAP measures assist management in planning, forecasting, and evaluating business and financial performance, including allocating resources.

Reconciliations of these non-GAAP measures to their most comparable reported GAAP measures are included in our earnings press release furnished to the SEC, which is available in the press room section of our website, thecronosgroup.com, these non-GAAP measures may not be comparable to measures used by other issuers. I’d also like to note that we are conducting our call today from our respective remote locations. As such, there may be brief delays cross talk or minor technical issues during this call. We thank you in advance for your patience and understanding. We will now make prepared remarks and then we will move into a question and answer session. With that I’ll pass it over to Cronos Group’s President and CEO, Kurt Schmidt.

Kurt T. Schmidt — President, Chief Executive Officer

Thank you, Shayne and good morning everyone. We appreciate your patience and for joining us for the second time in about two weeks. We are pleased to share our 2021 fourth quarter and full year results and business updates with you. As I touched on during our call in February 18th. We’ve started this year by undertaking a realignment of the business to position Cronos to drive profitable and sustainable long-term growth. This realignment puts our products and agility at the focal point. I view the realignment in three distinct pillars.

First, we have realigned the organization removing redundancy and centralizing functions under common leadership. Second, we are reducing complexity and continuing to our – and continuing our asset-light model. As part of that we have decided to exit the Peace Naturals Campus. I will elaborate more on these plans in a minute. We’re also continuing to perform product reviews and pricing optimization scenarios across our brands and products and finally, we have implemented a cost reduction initiatives. Expected to reduce operating expenses by approximately $20 million to $25 million in 2022.

When we spoke two weeks ago we bought you updates, primarily on the first and third pillars of our realignment initiative today, we’d like to provide a further development on the second pillar. This morning we announced in our earnings release that we are exiting our Peace Naturals Campus in Stayner, Ontario. Extensive analysis went into this decision and while we know this mean transition and change. We also know this is the right decision to help ensure Cronos’ long-term growth.

Our goal is always been operating asset like business. Focused on brands and R&D. This transition aligns us to that vision. We have always maintained that cultivation will shift to large scale agricultural specialists as the industry matures, which is why we focused on building joint ventures and partnerships around the world with best-in-class operators. We now feel confident that the industry and our supply chain in Canada are at a maturity level where we can implement this approach. We have consistently focused on having a diverse supply chain aided by contract manufacturers and third party producers to supplement our cultivation and manufacturing needs.

In addition to building those relationships over many years we have been developing capabilities with our JV partner Cronos GrowCo and order to execute this news. We are very pleased with their premium flower cultivation which has increasingly become an important component to our biomass supply and we know their capabilities and efficient downstream processing will enable our goal of improved profitability. Protecting top line growth and continued momentum on R&D is of the utmost importance for our go-forward strategy and they are top priorities for the transition. To ensure smooth execution Cronos will continue to operate the Peace Naturals Campus with a phase reduction and transition of activities throughout 2022, with the planned exit by the end of 2022.

In addition, we are focused on maintaining our relationship with our Canadian customers. We intend to obtain the sales license from Health Canada at close facility to ensure that continuity regarding our R&D efforts all initiatives and continuous plant across our various facilities. There will be many moving pieces and complexity to manage during this transition. But we’re focused on staying as close to our timeline as possible while maintaining our eye on growing revenue and bringing innovative products to market. We are grateful to our our standard associates for their hard work and contributions to Cronos Group and we appreciate those associates who will continue to work in our Peace Naturals Campus to provide a seamless transition out of the facility throughout this year.

I now want to turn to our business and walk you through some highlights from the fourth quarter and full year 2021. While this year had its challenges, it’s also important to note our wins all the fundamental work we have put into making our brand successful and win with the consumer is starting to shine through in our results. The Spinach brand continues to win in the Canadian market. In the fourth quarter SOURZ by Spinach Gummies continue to strengthen the double-digit market share in the category. All three SOURZ by Spinach flavors were in the top 10 in the edibles category nationally and within Ontario, blue raspberry holds the number one spot.

Our market share for Spinach in the flower category ended the quarter in the high single digits. The strength in the flower category is a result of years of R&D work and breeding and genetics. Importantly, we have shared a lot of the genetics with GrowCo and look forward to continuing to help them elevate our flower portfolio over time. We also launched our sub-brand Spinach Feelz, a brand, designed to deliver unique and enhance experiences.

Made possible through proprietary blends of rare cannabinoids alongside more common cannabinoid like THC and CBD with a wide variety of products and formats. In October 2021, we launched our first culture cannabis like product under Spinach Feelz, the Chill Bliss Gummy which is making significant inroads within the edibles category and although our based launch utilizing cultured CBG is early, we are happy with the trends. The success of our Spinach brands and products to date is a testament to getting the fundamentals right. We will continue to invest in our innovation to bring consumers the products they want and other products that haven’t been thought of.

We’re starting to see success in the Canadian market with spinach while readying ourselves to utilize our innovation and key market earnings and other markets as they emerge. As we restructure the organization to match our go-forward strategy. The primary focus of our energy will be towards elevating our brands but utilizing rare cannabinoid and focusing allied on adult-use products. We have always viewed the Canadian market as a region of fine-tune our innovation and product development initiatives. We will bring most of our adult use products to consumers in Canada, but we continue to conduct extensive consumer insight work and all the regions we operate in with an eye towards adult use in United stake. The United States remains a great place to learn more about the evolution of consumer preferences, while we focus on creating those turnkey solutions within the markets we operate in today.

Turning to Israel, we continue to be delighted with the results of our medical business we started selling our Peace Naturals brand, the medical patients through participating pharmacies in the second quarter of 2020. We have increased our distribution, the participating pharmacies to nearly all pharmacies that sell medical cannabis and we will continue to expand as more pharmacies come online. Total patient count in Israel has also increased substantially to approximately 109,000, which is up 40% versus the same period last year, with a long runway for continued growth and the recent survey conducted by cannabis magazine naming Peace Naturals the most recognized cannabis brand in Israel.

We have a lot to look forward to as we work towards meeting our patient demand in this market. Given the growth of our business we thought would take some time as I’m more into the Israeli market and how we positioned ourselves as a leader. Israel has a population of just over 9 million people and both — world’s highest cannabis usage rates. Unlike the North American cannabis market. Israel is much less competitive illicit market given stringent border controls in security infrastructure. The rapid growth in the Israeli medical market reminds us of the early days in Canada’s medical market with demand outpacing supply and the stigma associated with the product quickly fading away.

With our manufacturing footprint established local team, strong branded product portfolio, we are very well positioned to succeed in the Israeli market as we realign the organization to match our go-forward strategy. The primary focus of our energy will be towards elevating our brands by utilizing rare cannabinoids and focusing on adult use product. I want to conclude by outlining our four core business priorities, all of which are focused on driving initiatives aligned with our vision and designed to deliver sustained — sustainable growth.

In 2022, we look to one accelerate growth by focusing on the core business, leveraging our top selling products to deliver on each brand’s potential while maintaining a disciplined approach to investing our time and resources in the opportunities we believe will provide the most significant returns. Two, diligently evaluate our manufacturing strategies to ensure that we only move forward with new products and processes that are incremental value and contribute to our strategic vision.

Three, creating a robust platform for innovation across Cronos’ Group portfolio of global brands. Supported by our belief that rare cannabinoids will drive differentiation. Four, keep U.S. market entry as our North Star by managing our internal capital spend and external capital allocation to maintain the flexibility to capitalize on opportunities that will position Cronos as a leader in the U.S. market. We have a lot of work ahead of us, but I feel confident that the actions we’ve outlined today will improve our business and set us up for success in the long term. With that, I would like to pass it to our CFO, Bob Madore.

Robert L. Madore — Chief Financial Officer

Thanks, Kurt and good morning everyone. Before getting into financial results. Allow me to provide further details on our planned exit from our Peace Naturals Campus. As a result of the Company’s planned exit from the Peace Naturals Campus. The company has incurred a $119.9 million non-cash impairment charge on long-lived assets in the fourth quarter of 2021. In addition, the Company expects to incur charges of approximately $4.5 million in connection with the planned exit all which impact the ROW segment.

These charges include employee-related costs such as severance, relocation and other termination benefits, as well as contract termination and other related costs, which are expected to be incurred primarily in the second half of 2022. In addition, the company anticipates capital expenditures of approximately $2.5 million to modernize information technology systems and build distribution capabilities. Cronos Group looks forward to leveraging GrowCo’s capabilities and premium flower cultivation, and efficient downstream processing with the intention to improve profitability of the company’s Canadian operations.

In addition to further leveraging its joint venture with GrowCo, Cronos Group will continue to maintain a network of third party license processors to supplement cultivation and manufacturing needs. Now getting into the financial results filed today. In 2021 on a consolidated basis, we increased revenue to 59% year-over-year to $74.4 million with strong performance in the rest of the world segment, highlighted by Canada and Israel. Our rest of the world segment recorded net revenue in 2021 of $64.6 million representing a 73% increase year-over-year. The United States segment increased 4% year-over-year to $9.9 million. In light of slower growth in the U.S., we’re committed to rightsizing the U.S. segment to realign it with our go-forward strategy with a focus on improving profitability.

Now turning to in the fourth quarter of 2021 results. The company reported consolidated net revenue in the fourth quarter of 2021 of $25.8 million, a 51% increase from the prior year period. Revenue growth year-over-year was primarily driven by the continued growth in the adult use Canadian market and increased sales in the Israeli medical market. Consolidated gross profit for the fourth quarter of 2021 was $1.9 million representing a $16.8 million improvement from the fourth quarter of 2020. The improvement versus prior year was primarily driven by a decrease in inventory write downs and increased gross profit in the rest of the world segment.

Consolidated adjusted EBITDA in the fourth quarter of 2021 was negative $27.4 million representing a $25.8 million improvement from the fourth quarter of 2020. The improvement versus prior year was primarily driven by an improvement in gross profit and a decline in sales in marketing in research and development expenses. Turning to our reporting segments. In the rest of the world segment, we reported net revenue in the fourth quarter of 2021 of $22.7 million, a 68% increase from the prior year period. Revenue growth year-over-year was primarily driven by growth in both the adult use extracts and flower categories in Canada and sales in the Israeli medical market.

Gross profit for the rest of the world segment for the fourth quarter of 2021 was $2.4 million representing a $19.1 million improvement from the fourth quarter of 2020. The improvement versus prior year was primarily driven by a reduction in inventory write downs and an increase in sales volume of cannabis extracts in the Canadian market, which carries a higher gross profit than other product categories. Adjusted EBITDA in the rest of the world segment for the fourth quarter of 2021 was negative $14.6 million representing a $21.8 million improvement from the fourth quarter of 2020. The improvement versus prior year was primarily driven by in improvement in gross profit and a decrease in research and development expenses.

Turning to the U.S. segment, we reported net revenue in the fourth quarter of 2021 of $3.1 million, an 11% decrease from the prior year period. The decline year-over-year was driven by a reduction in volume due to competitive pressures. We spoke at length approximately 2 weeks ago that the U.S. CBD business is not where we want it to be. The strategic review, this business, including the potential for price optimization, SKU rationalization and modification of the distribution channels remain top of mind and we intend to share material updates with you at the appropriate time. Gross profit for the U.S. segment for the fourth quarter of 2021 was negative $0.5 million representing a $2.3 million decline from the fourth quarter of 2020.

The decline year-over-year was primarily due to increased production costs in increased inventory valuation adjustments to reflect net realizable value. Adjusted EBITDA in the U.S. segment for the fourth quarter 2021 was negative $8.3 million representing a $3.5 million improvement from the fourth quarter of 2020. The improvement versus prior [Technical Issue] primarily [Technical Issue] in sales and marketing and general and administrative expenses. Now turning to the balance sheet.

The company ended the quarter with approximately $1 billion in cash and short-term investments, which is down approximately $35 million from the third quarter of 2021. Capital expenditures for the quarter were $0.6 million with the spending focused across our global strategic priorities. Capital expenditures are down approximately 95% year-over-year driven by reduced spending on enterprise resource planning implementation in capital improvements across our facilities.

We remain committed to deploying capital in a disciplined manner and only in ways that align with our strategic priorities. Lastly, I would like to provide you an update on our remediation efforts in relation to the material weakness that we disclosed last quarter. We as a company are committed to instituting best practices for financial reporting, our management with oversight from the audit committee has initiated a plan, which we are working diligently to phase in over the course of 2022. In addition, I’m happy to state that the material weaknesses previously disclosed related to inventory verification have been remediated. With that I’ll turn it back to Kurt.

Kurt T. Schmidt — President, Chief Executive Officer

Thank you, Bob. It’s not lost on us that our recent challenges are overshadowing our results, but I want — but I want to leave you with today is that despite of all that you are starting to see the strategy and execution show up in our results, we are building a great brand in Canada through Spinach and have demonstrated sustainable market share gains. We are seeing incredible growth in Israel, a robust medical market we’ve — we worked hard to win it. We are making decisions to realign our organization and move quickly to help our business improve efficiencies and profitably in rapidly changing markets.

We are the first company to release a cultured cannabinoid product using breakthrough science and technology and we’re the leading company to market rare cannabinoid in a way that resonates with consumers. We’re on the right path and we’re rising to the challenges in front of us. With that, I’ll open the lines for questions.

Questions and Answers:

Operator

[Operator Instructions]

We have our first question comes from the line of Andrew Carter from Stifel. Your line is open. You may now ask your question.

Andrew Carter — Stifel — Analyst

Hey, thanks, good morning. First thing I wanted to ask is, how long has the kind of exit of Stayner being — been contemplated in terms of an option to kind of say fun and also kind of creating some of the redundancy — redundancies have because it’s — I would think like you would not — you would not want to put any risk to slowing down the revenue momentum. So maybe you could just help us with that. Thanks.

Kurt T. Schmidt — President, Chief Executive Officer

Yeah, this is Kurt. We’ve — this has been going for quite a lot while again the whole idea the whole GrowCo initiative is all about our belief that cultivation will move towards the agricultural sector. That’s why we created the GrowCo JV initially and we’re bearing that out. So, through construction, through start up and through fall up we’ve hit every milestone we want.

So that is on going for a while and we’re very pleased with where we’re at right now, we’re delivering high quality and well-priced cannabis out of the GrowCo supply chain and we have enough redundancy in our supply chain as we talked about in the in the upfront remarks that we feel very good that this is the right time for this move.

Andrew Carter — Stifel — Analyst

Okay, thanks and then just kind of second speaking on kind of the revenue momentum, great in the quarter it’s been a great build for the edibles brand, Spinach brands really stood out just released the headset data for February this morning, it’s taken a step back, both the edible and Spinach. Is that kind of — do you see that is kind of a seasonality anything you’re seeing in kind of reduced shipments and could kind of taking adult use revenue take a step back sequentially here in the calendar first quarter. Thanks.

Kurt T. Schmidt — President, Chief Executive Officer

Yeah, I think it’s — I think it’s part of a little bit of that seasonality, and some of COVID that came roaring back temporarily in the first quarter created some disruption. But again, I think we’re seeing overall, the momentum in the first quarter to be quite positive and the world is getting back to normal. I think in the second quarter here. So we think that that will right itself, we’re really confident about the way Spinach is developing on the consumer side.

Andrew Carter — Stifel — Analyst

Thanks, I’ll pass it on.

Operator

Our next question comes from the line of Rahul Gosar from Raymond James, your line is open. Please go ahead.

Michael Freedman — Raymond James — Analyst

Hi, there. Good morning, Kurt. Bob and Shayne, this is Michael Freedman on for Rahul Sarugaser this morning and one question, my first one is on sort of the downstream effects of this — of this exit from the Peace Naturals sites, I guess. I wonder if you could describe for us the implications on headcount implications on where your top notch R&D facilities might be moving to with this move and then just broader implications on cost structure as you go through this exit through 2022. Thanks very much.

Kurt T. Schmidt — President, Chief Executive Officer

Okay, next three things to unpack there. The first one is, I won’t go into the exact number of of the head count, but undoubtedly, as we go to shut down this facility, there will be changes in the size of the organization, no doubt about that. But we’re equally — we’re really committed and we’ve really planned this, it makes ensuring that we’re treating our employees the right way and we do this in a high quality fashion as we move through this process, but it will — it will have the effect of reducing the standard facility, including how many employees we have.

The second one on R&D, it’s important to remember, we have multiple facilities across the supply chain that the R&D works for — Winnipeg has a as a facility, we do R&D work there. We will eventually move some stuff into GrowCo and this has no effect on our R&D scope. So as we talked about in our key driver is brands and R&D and R&D is around margin accretive innovation and winning and we’ll see no effect. It’s going to have no effect on the innovation we’re developing in the timelines we are driving towards.

Then your third one I think was about margin profile in the business process? We don’t give specific guidance, but obviously making this decision, we obviously believe there is a significant opportunity to improve the profitability of our business. The Peace Naturals Campus compare — carries a real heavy complexity and the heavy overhead burden. So we’re moving that from our cost structure, right?

Coupled with the lower cost of production in the more efficient downstream processing at GrowCo which are experts in cultivation, we think there is a significant opportunity to expand gross profit in both dollar and percentage terms and remember, you’ve got a couple that with the — during our third quarter earnings call, where we announced the first phase of the restructuring, which will reduce operating costs by between $20 billion and $205 billion. So we believe all these initiatives put us on a really strong path and improved profitability while maintaining our clear focus on two very important things, which is margin accretive innovation, winning in rares and of course, sustainable growth and building our brands, particularly Spinach. That’s very helpful, Kurt. Thank you very much for that color and my follow-up is perhaps for Bob. We noticed beginning in the third quarter, some impairments related to the Ginkgo exclusive’s license and we see those again appearing on the four key financials, I wonder if you could just unpack these impairments and perhaps relates them to the way you’re valuing this Ginkgo exclusive license, thanks.

Robert L. Madore — Chief Financial Officer

Yeah, you know, one of the bigger challenges with going after the rare cannabinoids and developing the different milestones is that under the accounting rules, and I won’t bore everybody with the rules, but with the type of valuation methodology, the relief of royalty from royalty method in a space where you really don’t have any history, operational history and from a projection perspective they really kind of limited a little handcuffed in the valuation exercise and the level of growth you can put in the projections.

Just from a valuation perspective, that these valuations are not indicative of the commercial opportunities that we think these development of these rares has, for us it’s just an implication of heavily discounting future projections in a space that is very new rarified air over time as we get more experience in history around commercializing the opportunities as we developed additional rares, we have six more milestones to go after the two we’ve already completed. We think that history of commercialization and what the market represents and better visibility to that will help in that valuation exercise by — but by no means is it what we think it’s worth what we think we could sell it to third parties, we wanted to, we don’t — it’s just an accounting valuation method implication.

Michael Freedman — Raymond James — Analyst

Okay, thank you Bob, I’ll pass it on.

Operator

Our next question comes from the line of John Zamparo from CIBC. Your line is open please go ahead.

Michael Freedman — Raymond James — Analyst

Thank you very much. Good morning. I wanted to start on GrowCo. Can you say approximately what percent of your current sales either Q1 to date or in Q4 being supplied by GrowCo and Can you remind us what the terms are of purchasing from the JV? Are you paying for a market value or is there just got embedded in that?

Robert L. Madore — Chief Financial Officer

Yes. So our initial GrowCo purchases we actually really started in 2021. We’re a relatively small amount prior to that, Stayner or Stayner facility could not complete all of our supply and demand requirements. So in addition to GrowCo which is really just been up and running for the last 8 to 12 month period of time, we also utilized other third party cultivators to fulfill our biomass and dry flower needs. Now moving forward we obviously are looking to leverage just based on GrowCo’s success in the harvest that they’ve already had in sourcing quite a bit more from them.

From a pricing perspective, it’s competitive market pricing, relatively speaking. But much more efficient, effective and lower cost then what our costs were to produce it ourselves internally, hence the reason for the, the announcement this morning around Stayner. We just think large agri — growers like GrowCo that’s where we always kind of thought the action was going to be and what the future most effective and efficient, we are doing it and we felt — we feel like we’ve selected one of the best partners out there. So we’re excited about the opportunity.

John Zamparo — CIBC Capital Markets — Analyst

Okay, that’s helpful. Thank you. And then my second question is on the Israeli market and I wonder, when you take a step back, how you think this country will evolve over time. Will it continue to be served entirely by Canadian producers or do you think that eventually shift to a domestic supplied market? And I know you’ve got some exposure through Cronos Israel if and when that time comes. But just would like to get your thoughts on how that market will evolve.

Kurt T. Schmidt — President, Chief Executive Officer

Yeah, well, a lot of it will depend on the regulatory market in Israel. So, right now as the way, we — again, like we do everything, our cultivation is — we have a lot of redundancy built in. So, we import from Canada, we produce ourselves on our own cultivation with our joint venture on the converse, and we buy from third parties from Israel. So, we’re very well resourced. We think the biggest driver is going to be the market as it continues to grow and develop. Demand is certainly going up, and we feel fully — we are well positioned to be able to grow with that demand. So, we’re in a very good position in our mind.

John Zamparo — CIBC Capital Markets — Analyst

Understood. That’s all from me. Thank you.

Operator

Our next question comes from the line of Gaurav Jain from Barclays. Your line is open. Please go ahead.

Gaurav Jain — Barclays — Analyst

Hi, good morning. Thank you for taking my questions. So, you have reported a $27 million EBITDA loss this quarter. Would it be fair to assume that almost 80% of that loss is in the U.S. segment and 20% is in the rest of world segment?

Robert L. Madore — Chief Financial Officer

I’m sorry. Could you repeat that last sentence, the percentages you’re saying?

Gaurav Jain — Barclays — Analyst

On this $27 million loss, is it fair to assume that approximately $20 million of the loss will be in the U.S. segment and $8 million will be in the rest of the world segment?

Robert L. Madore — Chief Financial Officer

Yes. We break down EBITDA losses at that level.

Gaurav Jain — Barclays — Analyst

Sure. I guess, what I’m trying to get is, on your U.S. business, so, the commentary that you had that you’re rightsizing the business, it is not at the right place. I mean, you have made that comment a number of times over the last I would say couple of years, and still the business is only $10 million of sales. How do you fix it?

Robert L. Madore — Chief Financial Officer

As part of the strategic alignment — go ahead, Kurt.

Kurt T. Schmidt — President, Chief Executive Officer

Yeah. Well, clearly, we’re unhappy. We’re looking at — we still think — there’s still strong strength in those brands. One of the things we’re going to be focusing on more, as we said previously, is the adult-use side of the business. We’re going through that now. We just announced the leadership at the last earnings call, which was just two weeks ago. So, we’re doing that. We’re still doing the strategic review. With that said, we’ll come to the right conclusions as we go forward. But again, there’s still strength in those brands, they still resonate. And that’s what we’re about. We’re just not ready to announce anything. We’ll do that as we get closer.

Gaurav Jain — Barclays — Analyst

Sure, Kurt. My next question is, if I look at your market cap, roughly $1.3 million, net cash is about $1 billion. So, how do we think of Cronos? Like, would you use that $1 billion to invest in the spaces outside of cannabis where you could generate economic value because you and all your peers, I think everybody is struggling with the same issue that cannabis businesses have been pretty weak. So, would you look at something outside that business?

Kurt T. Schmidt — President, Chief Executive Officer

Yeah, I’ll let Mike chime in as well, our Chairman, because he’s leading it. Well, what — all the things we announced today are focused on brands, are focused on growing the business. It’s been an eye and the focus of the U.S. And giving us the financial — you’re right, we have a pretty strong balance sheet to make those kinds of investments that we want to make — potentially we can make in the U.S., which Mike actually has been leading for us.

A good example is the PharmaCann. They just announced this morning that they closed on their LivWell, acquisition. And the reason why we invested in the PharmaCann was the confidence we have in their management and their ability to strategically grow both, organically and M&A. You’re seeing that. And we have a partnership with them. And this is the kind of investments with our balance sheet we can make.

Mike, I don’t know if you want to add anything to this.

Michael Ryan Gorenstein — Executive Chairman

Sure. Thanks Kurt. Yes. The way we think of it is making investments that we think can have a really good ROI globally over time. So, things like the Spinach SOURZ, rare cannabinoids, the FEELZ line, that as markets open up, we’ll be able to take those products in as adult-use opens. So, things we invested in Canada we don’t look at as Canada standalone, but how can you take those and you see the performance head to head with the top U.S. brands, with other Canadian brands in Canada transitioning those into markets like Israel and U.S. as they open. In addition looking at that opportunities for brands or IP that we see in other markets, or infrastructure distribution partners in the U.S.

Gaurav Jain — Barclays — Analyst

Thanks a lot, Mike.

Operator

Our next question comes from the line of Andrew Bourne [Phonetic] from Jefferies.

Andrew — Jefferies — Analyst

Hey. Good morning. Andrew Bourne on the line for Owen Bennett. Thanks for taking our questions. So maybe just digging a little bit deeper into Israel, and I know we touched on it before but maybe closer to near-term. I wanted to get your expectations on how the strong momentum we’ve seen in third and fourth quarter might continue. Perhaps some stickiness there with the Peace Naturals brand. So, just wanted to get your thoughts on how Cronos be advantaged versus other LP selling in Israel, and how we should be thinking about the momentum moving forward as we look into 2022? Thanks.

Kurt T. Schmidt — President, Chief Executive Officer

Yeah, I think we have great momentum in the market, which as we talked about, is really doing well. We see that continuing as more pharmacies come on, and more patients come into medical cannabis, so that is a strong carrier. We think we’re competitively advantaged, because we have great series of brands, we cover all the segments we need to cover. As I said, we were rated as the most, the highest brand in Israel. And we have a great organization on the ground. So, we are — we have our own organization on the ground, they’re doing a great job in terms of sales and marketing, customer relationship, doctor relationship in the market. So, we feel we have a very strong organization on the ground with great brands.

And finally, we talked about our ability to serve the market. We are very well placed to serve the market. We use the same kind of strategy we’ve used in Canada. And we have the ability through the joint venture, third parties and what we do in Canada. So, we think, we’re well placed on it. And again, this is just going to be a market we see great momentum in the start of the New Year and we don’t see anything stopping us. It’s all about being focused on building great brands and great products, which not only is the Peace Naturals highly rated, but a lot of our products are highly rated in the top prescribed products.

Andrew — Jefferies — Analyst

Great, fantastic. Thanks for the color.

Operator

Our next question comes from the line of Michael Lavery from Piper Sandler. Your line is open, please go ahead.

Michael Lavery — Piper Sandler — Analyst

Thank you. Good morning. I joined a little late. Sorry. I hope this isn’t repetitive. But, can you just give an update on your relationship with Altria? And how — if or how that can help impact your U.S. operations, is there some opportunities there?

Kurt T. Schmidt — President, Chief Executive Officer

Well, Altria is a strategic investor in the Company. They have Board seats in there. They’re represented on the Board. And, again, they’ve been great at supporting us as we develop our business. As far as the U.S. one of the things we’ve done is the PharmaCann investments. So, that is — that’s a great example of the strength we have from the entire Board, both our independents are represented from GGP and of course Altria.

Michael Lavery — Piper Sandler — Analyst

Okay, thanks and can you just also maybe give an update on edibles, how the FEELZ brand is doing?

Kurt T. Schmidt — President, Chief Executive Officer

Yeah. We just talked about that. Yeah, the FEELZ brand is going fantastic. As we said, quoting the Hifyre data, we keep double-digit market share in edibles during the fourth quarter period. We see continued growth in 2022. If you look in our SOURZ portfolio, there’s three products in that line. They’re in the top 10, according LCS data. So, we are performing extremely well. And as we said, in October, we launched — under Spinach, we launched the FEELZ edibles, which is our first rare cannabinoids using CB and THC. And the progress — early progress, but we’re really pleased the way that’s developing. And along with that, we also launched our first rare cannabinoid-based product with CBG. That was done in January.

Michael Lavery — Piper Sandler — Analyst

Okay, great. Thanks so much.

Operator

[Operator Closing Remarks]

Disclaimer

This transcript is produced by AlphaStreet, Inc. While we strive to produce the best transcripts, it may contain misspellings and other inaccuracies. This transcript is provided as is without express or implied warranties of any kind. As with all our articles, AlphaStreet, Inc. does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company’s SEC filings. Neither the information nor any opinion expressed in this transcript constitutes a solicitation of the purchase or sale of securities or commodities. Any opinion expressed in the transcript does not necessarily reflect the views of AlphaStreet, Inc.

© COPYRIGHT 2021, AlphaStreet, Inc. All rights reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

Most Popular

MU Earnings: Micron’s Q4 profit declines but beats estimates

Micron Technology Inc. (NASDAQ: MU) Thursday said its fourth-quarter profit declined from last year, hurt by a sharp fall in revenues. Earnings, however, beat the market’s projection. On an adjusted

What are Philip Morris’ (PM) anticipations for the near term?

Shares of Philip Morris International Inc. (NYSE: PM) were down 1% on Thursday. The stock has dropped over 9% year-to-date. Although the tobacco industry has felt the pinch of inflation,

Key highlights from CarMax (KMX) Q2 2023 earnings results

CarMax, Inc. (NYSE:KMX) reported second quarter 2023 earnings results today. Net revenues rose 2% year-over-year to $8.1 billion. Net earnings were $125.9 million, or $0.79 per share, compared to $285.2 million,

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top